Polymer conjugates of mutated neublastin

Details Polymer conjugates of mutated neublastin Polymer conjugates of mutated neublastin

2003-01-31

2008-10-28

Kemmerer, Elizabeth C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Aftertreated polymer

C514S012200, C525S054100, C530S399000

Reexamination Certificate

active

07442370

ABSTRACT:
A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.

REFERENCES:
patent: 4883666 (1989-11-01), Sabel et al.
patent: 5084350 (1992-01-01), Chang et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5284761 (1994-02-01), Aebischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5414135 (1995-05-01), Snow et al.
patent: 5496804 (1996-03-01), Reed et al.
patent: 5618531 (1997-04-01), Cherksey
patent: 5733729 (1998-03-01), Lipshutz et al.
patent: 5754524 (1998-05-01), Wark
patent: 5770577 (1998-06-01), Fandl et al.
patent: 5795716 (1998-08-01), Chee et al.
patent: 5800992 (1998-09-01), Fodor et al.
patent: 5834029 (1998-11-01), Bellamkonda et al.
patent: 5846935 (1998-12-01), Panayotatos
patent: 5916555 (1999-06-01), Lee et al.
patent: 5939524 (1999-08-01), Bowditch et al.
patent: 6284540 (2001-09-01), Milbrandt et al.
patent: 6593133 (2003-07-01), Johansen et al.
patent: 6734284 (2004-05-01), Johansen et al.
patent: 2002/0055467 (2002-05-01), Johansen et al.
patent: 2004/0077543 (2004-04-01), Sah et al.
patent: 2004/0142418 (2004-07-01), Sah et al.
patent: 2004/0265972 (2004-12-01), Weintraub et al.
patent: WO 93/06116 (1993-04-01), None
patent: WO 97/08196 (1997-03-01), None
patent: WO 97/11964 (1997-04-01), None
patent: WO 98/32869 (1998-07-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/43813 (1999-09-01), None
patent: WO 00/01815 (2000-01-01), None
patent: WO 00/04050 (2000-01-01), None
patent: WO 00/18799 (2000-04-01), None
patent: WO 00/34475 (2000-06-01), None
patent: WO 00/73348 (2000-12-01), None
patent: WO 02/051433 (2002-07-01), None
patent: WO 02/060929 (2002-08-01), None
patent: WO 02/072826 (2002-09-01), None
patent: WO 02/078730 (2002-10-01), None
Vukicevic et al., 1996, PNAS USA 93:9021-9026.
Baudet et al., Development 127:4335-4344, 2000.
Choh, PNAS 77(6):3211-14, 1990.
Skolnick et al., 18(1):34-39, 2000.
Watabe et al., J. Neurosci. Res., 41:279-90, 1995.
Matsushita et al., Gene 203, 149-157, 1997.
PIR—80 Accession No. 14968.
Lin et al., Science 260(5111):1130-32, May 21, 1993.
Airaksmen et al. (1999), GDNF family neurotrophic factor signaling: four masters, one servant,Mol Cell Neurosci, 13:313-325.
Atschul et al. (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucl. Acids Res., 25:3389-3402.
Baloh, R.H. et al. (1998), “Artemm, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex,”Neuron, 21:1291-1302.
Baloh, R.H. et al. (2000), “Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalphail RET-specific agonists,”Journal of biological Chemistry, 275(5):3412-3420.
Borodovsky et al. (1995), “Detection of new genes in a bacterial genome using Markov models for three gene classes,”Nucl. Acids Res., 23:3554-3562.
Daopin et al. (1993), “Chrystal structure of TGF-β2 refined at 1.8 A resolution,”Proteins, 17:176-192.
Delgado, C. et al., (1992), “The uses and properties of PEG-Linked proteins,”Critical Reviews in Therapeutic Drug Carrier Systems, 9(3/4):249-304.
Eigenbrot and Gerber (1997), “X-ray structure of glial cell-derived neurotrophic factor at 1 9 A resolution and implications for receptor binding,”Nat. Struct. Biol., 4:435-438.
Finsen et al. (1992), “Somatostatin and neuropeptide Y in organotypic slice cultures of the rat hippocampus: an immunocytochemical and in situ hybridization study,”Neurosci, 47:105-113.
Francis, G.E., et al., (1998), “Pegylation of Cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques,”Int'l. Journal of Hematology, Elsevier Science Publishers, NL., 68(1):1-18.
GenBank™ Accession No. AA844072 (1998).
Lapchak (1977), “Therapeutic potential for glial cell line-derived neurotropic factor (GDNF) based upon pharmacological activities in the CNS,”Rev. Neurosci., 7:165-176).
Lapchak et al. (1996), “Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases,”Cell Tissue Res., 286:179-189.
Lin et al. (1993), GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons,Science, 260:1130-1132.
Lorenz et al. (1996), “Heteromultimeric CLC chloride channels with novel properties,”Proc. Natl. Acad. Sci USA, 93: 13362-13366.
Massague et al. (1994), “The TGF-β family and its composite receptor,”Trends Cell Biol., 4:172-178.
Masure et al. (1999), “Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells,”Eur. J. Biochem, 266:892-902.
McDonald and Hendrickson (1993), “A structural superfamily of growth factors containing a cystine knot motif.,”Cell, 73:421-424.
Milbrandt et al. (1998), Persephin, a novel neurotrophic factor related to GDNF and neurturin,Neuron, 20:245-253.
Reddy, K.R. (2000), “Controlled-release peylation, liposomal formulations: new mechanisms in the delivery of injectable drugs,”Annals of Pharmacotherapy, 34(7/8):915-923.
Robertson and Manson (1997), “The GDNF-RET signaling in partnership,”Trends Genet., 13:1-3.
Saarma and Sariola (1999),Microscopy Res.&Technique, 45:292-302.
Sanicola et al. (1997), “Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins,”Proc Natl Acad Sci USA, 94:6238-6243.
Sauer and Oertel (1994), “Progressive degeneration of nigrostriatal dopamine neurons following intrastraiatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat,”Neuroscience, 59:401-415.
Slooth and Gramsbergen (1995), “Detection of salicylate and its hydroxylated adducts 2.3- and 2.5- dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue,”J. Neurosci. Meth., 60:141-149.
Stoppini et al. (1991), “A simple method for organotypic cultures of nervous tissue,”J. Neurosci. Methods, 37:173-182.
Thompson et al. (1997), “The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools,”Nucl. Acids Res., 25:4876-4882.
Unsicker (1996), “GDNF: a cytokine at the interface of TGF-betas and neurotrophins,”Cell Tissue Res., 286:175-178.
Von Schwedler et al. (1993), “Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells,”J. Virol., 67:4945-4955.
Zufferey et al. (1997), “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,”Nat. Biotechnol., 15:871-875.
Rosenblad, C., et al., “In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin,”Molecular and Cellular Neuroscience15:199-214 (2000).

Affiliated with

Also associated with

Rating

Polymer conjugates of mutated neublastin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymer conjugates of mutated neublastin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer conjugates of mutated neublastin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3991843